PCM
ACOR

Prelude Capital Management’s Acorda Therapeutics ACOR Stock Holding History

Prelude Capital Management’s Portfolio ACOR Stock Details ACOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-53
Closed -$5K – 2506
2020
Q2 		$5K Buy
+53
New +$5.6K ﹤0.01% 1729
2019
Q1 		– Sell
-6
Closed -$12K – 2305
2018
Q4 		$12K Buy
6
+1
+20% +$2.18K ﹤0.01% 1348
2018
Q3 		$11K Buy
+5
New +$15.5K ﹤0.01% 1442
2018
Q2 		– Sell
-15
Closed -$43K – 2024
2018
Q1 		$43K Sell
15
-13
-46% -$38.9K ﹤0.01% 1130
2017
Q4 		$73K Sell
28
-1
-3% -$2.84K 0.01% 865
2017
Q3 		$83K Sell
29
-55
-65% -$145K 0.01% 943
2017
Q2 		$199K Sell
84
-3
-3% -$5.94K 0.02% 581
2017
Q1 		$219K Sell
87
-64
-42% -$184K 0.02% 534
2016
Q4 		$341K Buy
+151
New +$359K 0.04% 400
2016
Q3 		– Sell
-93
Closed -$286K – 1886
2016
Q2 		$286K Buy
93
+77
+481% +$250K 0.04% 401
2016
Q1 		$50K Buy
+16
New +$66.4K 0.01% 976
2015
Q3 		– Sell
-17
Closed -$67K – 1879
2015
Q2 		$67K Buy
17
+5
+42% +$19.3K 0.01% 1045
2015
Q1 		$47K Sell
12
-28
-70% -$128K 0.01% 1320
2014
Q4 		$196K Hold
40
– – 0.03% 655
2014
Q3 		$163K Buy
40
+8
+25% +$30K 0.02% 801
2014
Q2 		$128K Buy
32
+12
+60% +$48.9K 0.02% 993
2014
Q1 		$91K Sell
20
-24
-55% -$97K 0.01% 1051
2013
Q4 		$153K Hold
44
– – 0.03% 692
2013
Q3 		$182K Sell
44
-66
-60% -$284K 0.03% 571
2013
Q2 		$434K Buy
+110
New +$453K 0.09% 283

Other funds holding ACOR

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Parallax Volatility Advisers
Parallax Volatility Advisers San Francisco, California $38.6B AUM 45.89% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Prelude Capital Management's ACOR Position: Q3 2020 in Review

Prelude Capital Management sold out of Acorda Therapeutics (ACOR) in Q3 2020, closing a stake of 53 shares — an estimated $5K sold.

Prelude Capital Management first reported a position in ACOR in Q2 2013 and held it in 20 quarters. The position peaked at $434K in Q2 2013. 60 funds tracked by Wall St. Rank hold ACOR as of Q3 2020.

  • Prelude Capital Management reported no remaining Acorda Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Prelude Capital Management sold 53 Acorda Therapeutics shares in Q3 2020, an estimated $5K.
  • Prelude Capital Management first reported a position in Acorda Therapeutics in Q2 2013 and held it in 20 quarters.
  • Prelude Capital Management's Acorda Therapeutics position peaked at $434K in Q2 2013.
  • 60 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q3 2020.

Based on Prelude Capital Management's 13F filing for Q3 2020, filed 16 Nov 2020.